Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China National Biotec Group

http://www.cnbg.com.cn

Latest From China National Biotec Group

Boosters Miss Growth Expectations Despite China COVID Surge

While two Chinese companies gained domestic approvals for their recombinant protein and adenovirus-based COVID-19 shots as heterologous boosters in February, these currently only account for roughly 21% of all booster shots, showing the continued predominance of inactivated virus-based technology in the country.

China Coronavirus COVID-19

China OKs Heterologous Booster Shots Amid Heated COVID Vaccine Race

CanSino and Zhifei have received the regulatory green light for their respective COVID-19 booster shots in China and an estimated $1.3bn vaccine market is now up for grabs. Domestic contenders are set to elbow each other in the sector with a range of viral vector, recombinant protein and mRNA-based jabs.

China Approvals

Pfizer, CStone Score China's Seventh Immuno-Oncology Approval

Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.

China Approvals

With No mRNA Vaccines In Sight, Frustration Grows In China

A top virologist and prominent Chinese researcher sounds alarm over reluctance to clear mRNA vaccines amid regional outbreaks and the government rollout of inactivated virus-based booster shots without real-word evidence.

Coronavirus COVID-19 Policy
See All

Company Information

UsernamePublicRestriction

Register